Taiji Sawamoto

906 total citations
30 papers, 644 citations indexed

About

Taiji Sawamoto is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Taiji Sawamoto has authored 30 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Surgery and 8 papers in Molecular Biology. Recurrent topics in Taiji Sawamoto's work include Urinary Bladder and Prostate Research (6 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). Taiji Sawamoto is often cited by papers focused on Urinary Bladder and Prostate Research (6 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). Taiji Sawamoto collaborates with scholars based in Japan, United States and Netherlands. Taiji Sawamoto's co-authors include Yuji Kurosaki, Toshikiro Kimura, Kazutaka Higaki, Masataka Katashima, Marcel van Gelderen, James J. Keirns, Sumihisa Kimura, Selina Moy, Takehisa Hata and Yuji Tokunaga and has published in prestigious journals such as PLoS ONE, International Journal of Pharmaceutics and Journal of Cerebral Blood Flow & Metabolism.

In The Last Decade

Taiji Sawamoto

30 papers receiving 616 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Taiji Sawamoto Japan 17 160 159 120 101 100 30 644
Ronald Goldwater United States 12 190 1.2× 37 0.2× 44 0.4× 118 1.2× 136 1.4× 32 708
Jennifer Soung United States 15 71 0.4× 54 0.3× 32 0.3× 36 0.4× 60 0.6× 45 952
Yonghua Wang China 19 73 0.5× 296 1.9× 24 0.2× 44 0.4× 385 3.9× 68 1.1k
Kesavan Esuvaranathan Singapore 22 135 0.8× 145 0.9× 160 1.3× 28 0.3× 569 5.7× 64 1.3k
Chengda Zhang China 14 81 0.5× 39 0.2× 19 0.2× 94 0.9× 125 1.3× 49 553
Xander M.R. van Wijk United States 14 56 0.3× 28 0.2× 49 0.4× 46 0.5× 163 1.6× 45 557
Taiichi Kaku Japan 19 126 0.8× 390 2.5× 7 0.1× 29 0.3× 117 1.2× 39 793
Alina Ostrowska United States 17 128 0.8× 194 1.2× 28 0.2× 12 0.1× 356 3.6× 39 1.2k
Chao-Hsiang Chang Taiwan 17 147 0.9× 151 0.9× 63 0.5× 29 0.3× 382 3.8× 46 991
G.M. Murphy United Kingdom 20 246 1.5× 337 2.1× 5 0.0× 26 0.3× 144 1.4× 57 1.1k

Countries citing papers authored by Taiji Sawamoto

Since Specialization
Citations

This map shows the geographic impact of Taiji Sawamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taiji Sawamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taiji Sawamoto more than expected).

Fields of papers citing papers by Taiji Sawamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taiji Sawamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taiji Sawamoto. The network helps show where Taiji Sawamoto may publish in the future.

Co-authorship network of co-authors of Taiji Sawamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Taiji Sawamoto. A scholar is included among the top collaborators of Taiji Sawamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taiji Sawamoto. Taiji Sawamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fushiki, Hiroshi, et al.. (2024). Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets. Journal of Pharmacological Sciences. 156(3). 161–170. 11 indexed citations
2.
Zhu, Tong, Selina Moy, Udaya Valluri, et al.. (2020). Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis. Clinical Drug Investigation. 40(9). 827–838. 4 indexed citations
3.
Nomura, Yuki, Junko Toyoshima, Atsunori Kaibara, et al.. (2016). Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females. Drug Metabolism and Pharmacokinetics. 31(6). 411–416. 8 indexed citations
4.
Katashima, Masataka, Atsunori Kaibara, Koji Chono, et al.. (2016). Integrative pharmacokinetic–pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes. Drug Metabolism and Pharmacokinetics. 31(4). 323–332. 2 indexed citations
5.
Gelderen, Marcel van, et al.. (2015). Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. Clinical Therapeutics. 37(5). 1031–1044. 18 indexed citations
6.
7.
Kawamura, Akio, Manabu Murakami, Taiji Sawamoto, et al.. (2014). Assessment of Tacrolimus Absorption From the Human Intestinal Tract: Open-Label, Randomized, 4-Way Crossover Study. Clinical Therapeutics. 36(5). 748–759. 40 indexed citations
8.
Lee, Jennifer, Selina Moy, John Meijer, et al.. (2013). Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a β3-Adrenoceptor Agonist. Clinical Drug Investigation. 33(6). 429–440. 23 indexed citations
9.
Nakaoka, Hirofumi, Shigeki Mitsunaga, Kazuyoshi Hosomichi, et al.. (2013). Detection of Ancestry Informative HLA Alleles Confirms the Admixed Origins of Japanese Population. PLoS ONE. 8(4). e60793–e60793. 23 indexed citations
10.
Lee, Jennifer, Wenhui Zhang, Selina Moy, et al.. (2013). Effects of Food Intake on the Pharmacokinetic Properties of Mirabegron Oral Controlled-Absorption System: A Single-Dose, Randomized, Crossover Study in Healthy Adults. Clinical Therapeutics. 35(3). 333–341. 17 indexed citations
11.
Lee, Jennifer, Marloes Schaddelee, Wenhui Zhang, et al.. (2012). Single dose pharmacokinetics and absolute bioavailability of mirabegron, a ?3-adrenoceptor agonist for treatment of overactive bladder. International Journal of Clinical Pharmacology and Therapeutics. 50(11). 838–850. 42 indexed citations
12.
Katashima, Masataka, et al.. (2012). Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non‐Hodgkin lymphoma. Biopharmaceutics & Drug Disposition. 34(2). 137–140. 3 indexed citations
13.
14.
Dickinson, James, Taiji Sawamoto, Walter Krauwinkel, et al.. (2012). Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron. Clinical Drug Investigation. 33(1). 11–23. 24 indexed citations
15.
16.
Smith, P. Brian, Thomas J. Walsh, William Hope, et al.. (2009). Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. The Pediatric Infectious Disease Journal. 28(5). 412–415. 104 indexed citations
17.
Krueger, Gerald G., Lawrence F. Eichenfield, J. John Goodman, et al.. (2007). Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis.. PubMed. 6(2). 185–93. 23 indexed citations
18.
Hirabayashi, Hideki, et al.. (2001). Relationship Between Physicochemical and Osteotropic Properties of Bisphosphonic Derivatives: Rational Design for Osteotropic Drug Delivery System (ODDS). Pharmaceutical Research. 18(5). 646–651. 26 indexed citations
19.
Sawamoto, Taiji, et al.. (1997). Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability. Journal of Pharmacy and Pharmacology. 49(4). 450–457. 64 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ronald Goldwater Breakdown of academic impact, for papers by Jennifer Soung Breakdown of academic impact, for papers by Yonghua Wang Breakdown of academic impact, for papers by Kesavan Esuvaranathan Breakdown of academic impact, for papers by Chengda Zhang Breakdown of academic impact, for papers by Xander M.R. van Wijk Breakdown of academic impact, for papers by Taiichi Kaku Breakdown of academic impact, for papers by Alina Ostrowska Breakdown of academic impact, for papers by Chao-Hsiang Chang Breakdown of academic impact, for papers by G.M. Murphy
Rankless by CCL
2026